StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines gAAP SG&A Expense as % of Product Sales (%) (%)

Form 8-K EX-99.1 Earnings Releases

QuarterlyAnnual
Latest, Q2 2026
35.0%
Period ended Jun 30, 2026
Change on a year earlier
-6.0 pts
41.0% in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP SG&A Expense as % of Product Sales (%) (%)Year on yearSource
Q2 2026Jun 30, 202635.0%-6.0 ptsForm 8-K (filed 2026-08-05) ↗
Q1 2026Mar 31, 202637.0%-4.0 ptsForm 8-K (filed 2026-05-06) ↗
Q4 2025Dec 31, 202538.0%-7.0 ptsForm 8-K (filed 2026-02-26) ↗
Q3 2025Sep 30, 202538.0%-8.0 ptsForm 8-K (filed 2025-11-06) ↗
Q2 2025Jun 30, 202541.0%-7.0 ptsForm 8-K (filed 2025-08-06) ↗
Q1 2025Mar 31, 202541.0%-16.0 ptsForm 8-K (filed 2025-05-07) ↗
Q4 2024Dec 31, 202445.0%-21.0 ptsForm 8-K (filed 2026-02-26) ↗
Q3 2024Sep 30, 202446.0%-15.0 ptsForm 8-K (filed 2024-11-12) ↗
Q2 2024Jun 30, 202448.0%-23.0 ptsForm 8-K (filed 2024-08-07) ↗
Q1 2024Mar 31, 202457.0%-23.0 ptsForm 8-K (filed 2024-05-08) ↗
Q4 2023Dec 31, 202366.0%–Form 8-K (filed 2025-02-27) ↗
Q3 2023Sep 30, 202361.0%–Form 8-K (filed 2024-11-12) ↗
Q2 2023Jun 30, 202371.0%–Form 8-K (filed 2024-08-07) ↗
Q1 2023Mar 31, 202380.0%–Form 8-K (filed 2024-05-08) ↗

Cite this data

StockData. (2026). BeOne Medicines GAAP SG&A Expense as % of Product Sales (%) (%), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/sga_pct_prod_rev

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.